Serna Bio reports using the Nebius platform to accelerate RNA structure-function mapping and investigate the transcriptome as a drug target. Its discovery platform combines proprietary data and computational pipelines to identify functional RNA structures and design small molecules that modulate RNA biology.
Nebius named Serna Bio the second-place winner in the drug discovery category of its inaugural AI Discovery Awards. The award program provided GPU credits for Nebius AI Cloud to category winners and runners-up. Serna Bio subsequently described its actual platform use in its own announcement.
Serna Bio reports Nebius platform usePublished 18 Jul 2025 · LinkedIn · Web pageSerna Bio reports using the Nebius platform to accelerate RNA structure-function mapping and investigate the transcriptome as a drug target.
Nebius announces AI Discovery Award support
Published 23 Jun 2025 · Nebius · Web page
Nebius states that AI Discovery Awards category winners and runners-up receive GPU credits for Nebius AI Cloud, alongside mentorship and networking support.
Nebius announces AI Discovery Award supportPublished 23 Jun 2025 · Nebius · Web pageNebius states that AI Discovery Awards category winners and runners-up receive GPU credits for Nebius AI Cloud, alongside mentorship and networking support.
Nebius AI Discovery Award 2025
Listed 27 Oct 2026 · Nebius · Web page
Nebius lists Serna Bio as an AI Discovery Award nominee and describes its RNA drug discovery business.
Nebius AI Discovery Award 2025Listed 27 Oct 2026 · Nebius · Web pageNebius lists Serna Bio as an AI Discovery Award nominee and describes its RNA drug discovery business.
Nebius names Serna Bio an award winner
Listed 27 Oct 2026 · LinkedIn · Web page
Nebius names Serna Bio as the second-place winner in the drug discovery category of its AI Discovery Award.
Nebius names Serna Bio an award winnerListed 27 Oct 2026 · LinkedIn · Web pageNebius names Serna Bio as the second-place winner in the drug discovery category of its AI Discovery Award.
AI Discovery Award winners receive Nebius credits
Published 19 Jun 2025 · LinkedIn · Web page
Artem Elmuratov lists Serna Bio among the award winners and states that all winners receive Nebius cloud credits and additional support.
AI Discovery Award winners receive Nebius creditsPublished 19 Jun 2025 · LinkedIn · Web pageArtem Elmuratov lists Serna Bio among the award winners and states that all winners receive Nebius cloud credits and additional support.
Serna Bio, operated by Ladder Therapeutics, develops small-molecule drugs that target RNA to regulate protein expression and splicing. Its discovery platform combines experimental RNA-structure data, screening assays and AI chemistry tools to identify targets, discover compounds and optimize drug candidates. The company uses the platform for its own therapeutic pipeline and collaborations with pharmaceutical companies. Its programs include ALS and respiratory diseases, alongside work targeting JAK/STAT and Hippo/YAP-TAZ signaling. A collaboration with Chiesi focuses on discovering RNA-targeted treatments for respiratory diseases.
Documented financing · private company
AmountUndisclosedEisai Golden Ticket award — in-kind laboratory support
Serna Bio develops small molecules that modulate RNA function for drug discovery. · Health
How they use Nebius AI Cloud
Serna Bio reports using the Nebius platform to accelerate RNA structure-function mapping and investigate the transcriptome as a drug target. Its discovery platform combines proprietary data and computational pipelines to identify functional RNA structures and design small molecules that modulate RNA biology.
Nebius named Serna Bio the second-place winner in the drug discovery category of its inaugural AI Discovery Awards. The award program provided GPU credits for Nebius AI Cloud to category winners and runners-up. Serna Bio subsequently described its actual platform use in its own announcement.
Serna Bio reports Nebius platform usePublished 18 Jul 2025 · LinkedIn · Web pageSerna Bio reports using the Nebius platform to accelerate RNA structure-function mapping and investigate the transcriptome as a drug target.
Nebius announces AI Discovery Award support
Published 23 Jun 2025 · Nebius · Web page
Nebius states that AI Discovery Awards category winners and runners-up receive GPU credits for Nebius AI Cloud, alongside mentorship and networking support.
Nebius announces AI Discovery Award supportPublished 23 Jun 2025 · Nebius · Web pageNebius states that AI Discovery Awards category winners and runners-up receive GPU credits for Nebius AI Cloud, alongside mentorship and networking support.
Nebius AI Discovery Award 2025
Listed 27 Oct 2026 · Nebius · Web page
Nebius lists Serna Bio as an AI Discovery Award nominee and describes its RNA drug discovery business.
Nebius AI Discovery Award 2025Listed 27 Oct 2026 · Nebius · Web pageNebius lists Serna Bio as an AI Discovery Award nominee and describes its RNA drug discovery business.
Nebius names Serna Bio an award winner
Listed 27 Oct 2026 · LinkedIn · Web page
Nebius names Serna Bio as the second-place winner in the drug discovery category of its AI Discovery Award.
Nebius names Serna Bio an award winnerListed 27 Oct 2026 · LinkedIn · Web pageNebius names Serna Bio as the second-place winner in the drug discovery category of its AI Discovery Award.
AI Discovery Award winners receive Nebius credits
Published 19 Jun 2025 · LinkedIn · Web page
Artem Elmuratov lists Serna Bio among the award winners and states that all winners receive Nebius cloud credits and additional support.
AI Discovery Award winners receive Nebius creditsPublished 19 Jun 2025 · LinkedIn · Web pageArtem Elmuratov lists Serna Bio among the award winners and states that all winners receive Nebius cloud credits and additional support.
Serna Bio, operated by Ladder Therapeutics, develops small-molecule drugs that target RNA to regulate protein expression and splicing. Its discovery platform combines experimental RNA-structure data, screening assays and AI chemistry tools to identify targets, discover compounds and optimize drug candidates. The company uses the platform for its own therapeutic pipeline and collaborations with pharmaceutical companies. Its programs include ALS and respiratory diseases, alongside work targeting JAK/STAT and Hippo/YAP-TAZ signaling. A collaboration with Chiesi focuses on discovering RNA-targeted treatments for respiratory diseases.
Documented financing · private company
AmountUndisclosedEisai Golden Ticket award — in-kind laboratory support
